| Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. Co.'s platforms which include Dolaflexin and Dolasynthen, delivering its DolaLock payload, as well as Immunosynthen. Co.'s product candidates include XMT-1536 and XMT-1592. XMT-1536, an ADC utilizing Co.'s Dolaflexin platform and targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma is astudy including both a dose escalation cohort and two expansion cohorts in ovarian cancer and NSCLC adenocarcinoma. XMT-1592 uses one of Co.'s new platforms, Dolasynthen, and also targets NaPi2b. We show 18 historical shares outstanding datapoints in our coverage of MRSN's shares outstanding history.|
Understanding the changing numbers of MRSN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MRSN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MRSN by allowing them to research MRSN shares outstanding history
as well as any other stock in our coverage universe.